Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Gene Variations Can Predict Radiation-Induced Toxicity Risk

By BiotechDaily International staff writers
Posted on 04 Aug 2014
Key genetic variants may affect how cancer patients respond to radiation treatments, according to new research. Scientists discovered that differences in the TANC1 (tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1) gene are associated with a greater risk for radiation-fueled side effects in prostate cancer patients, which include impotence, diarrhea, and incontinence.

These findings, published July 2014 in Nature Genetics, are based on a genome-wide association study, a type of study in which researchers studied a variety of genetic variants to see if any of them are tied to a specific type of complication, which could sometimes appear years after treatment was completed.

“Our findings, which were replicated in two additional patient groups, represent a significant step towards developing personalized treatment plans for prostate cancer patients,” said Barry S. Rosenstein, PhD, professor, radiation oncology, genetics and genomic sciences, Icahn School of Medicine at Mount Sinai (New York, NY, USA), the lead Mount Sinai investigator on the study. “Within five years, through the use of a predictive genomic test that will be created using the data obtained in the recent study, it may be possible to optimize treatment for a large number of cancer patients.”

For the study, Dr. Rosenstein and his colleagues obtained blood samples from nearly 400 patients who were receiving radiotherapy treatment for prostate cancer. The blood samples were screened for roughly one million genetic markers, and each patient was monitored for at least two years to monitor incidents of side effects from the radiation. Data analysis revealed which genetic markers were consistently associated with the development of complications following radiotherapy.

“The next step is to validate the results, and see if the same markers predict similar outcomes in patients with other forms of cancer,” said Dr. Rosenstein. Using the genomic test being developed, treatment plans can be adjusted to curtail adverse effects thereby allowing for an improved quality life for many cancer survivors.

Related Links:

Icahn School of Medicine at Mount Sinai



view channel
Image: Schematic representation of HIV DART binding to two distinct antigens simultaneously, redirecting the killer T-cells to destroy HIV-1 infected cells (Photo courtesy of Duke University).

Bi-Specific Antibodies Shown to Clear Latent HIV Infections

Bi-specific antibodies or DARTS (dual-affinity re-targeting proteins) have been used to eliminate latent HIV-infection from patient samples by redirecting polyclonal T-cells to specifically engage with... Read more

Drug Discovery

view channel
Image: Use of catchphrase terms like “breakthrough” and “promising” in public news media presenting new drugs tends to result in incorrect assumptions and conclusions about the meaning and significance of criteria for FDA breakthrough-designated and accelerated-approval drugs (Photo courtesy of Dartmouth Institute).

Words That Inappropriately Enhance Perception of New Drug’s Effectiveness

Researchers have found that using the words “breakthrough” and “promising” in presenting a new drug to the general public often has a dramatic effect on judgment about its effectiveness.... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Sale of Mexican Pharmaceutical Company Expected to Boost Latin American Prescription Drug Market

The sale of a major Mexican pharmaceutical company to an international generic drug corporation is expected to accelerate the growth of the Latin American market for prescription drugs. Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel) announced that it has entered into definitive agreements to buy Representaciones... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.